Abstract: A drink and mist bottle cap is detachably attachable to a bottle to enable a person to produce a mist from a pump and mist nozzle and also drink from a drink spout. A drinking spout has a drink spout cap that is detachably attachable over the drinking spout to seal the liquid contents within the bottle when not drinking form the bottle. The drink and mist bottle cap may also have an anti-backwash valve that is configured to prevent backwash from flowing back into the interior of the bottle and an ultraviolet light configured to produce a disinfecting ultraviolet light within the bottle, and a pressure relief valve to allow pressure equalization when there is a pressure differential between the interior of the bottle and the exterior of the bottle.

Abstract: The present invention relates to an electric Drink and Mist Bottle Cap apparatus and system. The electric Drink and Mist Bottle Cap apparatus and system allows a user to drink and mist without changing fittings or fitting settings. This invention attaches to existing bottles, delivers a fine mist, and is rechargeable. The present invention allows a user to readily drink and mist from an existing water bottle.

Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Abstract: A method to drawdown pipe sections with the use or regulation control of flaring and cross-compression technique. The method allows to evacuate a fluid mixture from a drawdown section. The fluid mixture typically contains a liquid phase and a gas phase. The method includes flowing the fluid mixture from the drawdown section towards a separation vessel, and then out of the separation vessel to simultaneously flow the gas phase towards a flare for burning and flow the liquid phase towards one or more pumps towards an adjoining section. The proposed method allows recovering a higher proportion of the fluid mixture, as recycled product, and therefore limiting the combustion of the gas phase towards the atmosphere.

Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.

Abstract: A method that includes the step of using a person's fingers to push a dental composition into engagement with a damaged tooth surface of a damaged tooth thereby adhering the dental composition to the damaged tooth surface and covering at least a portion of the damaged tooth surface. The dental composition includes a base material comprising at least one of the following compounds chosen from the group consisting of: a product consisting of one or more hydrocarbon-based waxes that may also include inorganic fillers and/or organic fillers; an uncured, uncrosslinked silicone high consistency rubber base; and a hydrophobic water insoluble solid material. The base material has a coating composition on one or more surface of the base material wherein the coating composition comprises: one or more desensitization ingredient and at least one dry, powdered hydrophilic polymeric substance.

Abstract: An actuator for a separate downhole tool, including an electric linear actuator, a latch driven by the linear actuator and configured to interact with and operate a movable component of the separate tool. A subsurface safety valve system, including a subsurface safety valve having a flow tube, the valve lacking an operable actuator, and an actuator runnable into the valve, the actuator latchable to the valve to operate the flow tube. A method for controlling a well including installing a subsurface safety valve in a tubing string at a target location in a borehole of the well, the subsurface safety valve lacking an actuator, running an actuator to the valve, engaging the actuator with the valve, and operating the valve with the actuator. A borehole system including a borehole in a subsurface formation, a string in the borehole, and an actuator disposed within or as a part of the string.

Abstract: A glass container for storing pharmaceutical formulations may include a glass body formed from a Type IA or Type IB glass composition according to ASTM Standard E438-92(2011). The glass body may include a wall portion with an inner surface and an outer surface, a heel portion and a floor portion, wherein the inner surface of the glass container is formed by the inner surface of the glass body. The glass body may include at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. The glass container does not comprise a boron-rich layer on the inner surface of the glass body in as formed condition.

Abstract: Systems, methods, and other embodiments associated with output production are described. One example system comprises an analysis component configured to analyze a data set to produce an evaluation result. The system also comprises a production component configured to produce a rendered output based, at least in part, on the evaluation result, where the rendered output is stored in a computer-readable medium.

Abstract: The present disclosure relates to medicament injection devices. An injection device includes: a movable dosage programming component comprising a rotary encoder system having a predefined angular periodicity, a sensor arrangement including a first optical sensor configured to detect movement of the movable dosage programming component relative to the sensor arrangement during dosing of a medicament, wherein the first optical sensor is configured to operate in a strobe-sampling mode at a first frequency, a second optical sensor configured to detect movement of the rotary encoder system relative to the second optical sensor wherein the second optical sensor is configured to operate in a strobe-sampling mode at a second frequency lower than the first frequency, and a processor arrangement configured to, based on the detected movement, determine a medicament dosage administered by the injection device.

Abstract: A coated glass pharmaceutical package includes a glass body having a Type 1 chemical durability according to USP 660, at least a class A2 base resistance or better according to ISO 695, and at least a type HGB2 hydrolytic resistance or better according to ISO 719, the glass body having an interior surface and an exterior surface and a wall extending therebetween. A lubricous coating having a thickness of less than or equal to 90 nm may be positioned on at least a portion of the exterior surface of the glass body but not on any portion of the interior surface. The portion of the coated glass package with the lubricous coating comprises a coefficient of friction that is at least 20% less than an uncoated glass package and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation cycle including exposure to a temperature of 250° C. for a time period of 30 minutes.

Abstract: Pouches are disclosed that can incorporate components in addition to consumables such as nicotine. Such components can include tooth whitening substances, oral antiseptics, gum or tooth health substances, vitamins, medicaments, and others. Such components can be provided within a pouch with the consumable, be impregnated into a pouch material, or be coated onto a pouch.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: Some embodiments are directed to a container for dispensing a flowable solid (e.g., powder) that comprises an interior volume and a partition separating the interior volume into a storage volume and a passage. The passage may include a dosing chamber and a passage. The storage volume may be in direct communication with the dosing chamber. The storage volume may include a floor positioned above the dosing chamber. The outlet passage may extend from the dosing chamber to an outlet. The partition may extend below the floor of the storage volume such that the partition restricts the flow of the flowable solid from the storage volume when the container is at least partially inverted to dispense a dose of flowable solid each time the container is at least partially inverted. The container may consistently dispense equal doses of flowable solid regardless the amount of flowable solid remaining in the storage volume.

Abstract: The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.

Abstract: Computerized methods are disclosed for automated question generation from source documents through natural language processing, for applications including training and testing. Interleaved selection and transformation phases employ combined semantic-syntactic analysis to progressively refine natural input text into a high density of text fragments having high content value. Non-local semantic content and attributes such as emphasis attributes can be attached to the text fragments. The text fragments are reverse parsed by matching against a precomputed library of combined semantic-syntactic patterns. Once the patterns of each fragment are determined, transformation of fragments into question-answer pairs is performed using question selectors and answer selectors tailored to each pattern. Methods for constructing distractors, both internal and external, are also disclosed. The ecosystem of machine learning components, ontology resources, and process improvement are also described.